eXoZymes prices offering of stock-and-warrant units for $18 each

eXoZymes Inc., trading on Nasdaq under "EXOZ," priced a prospectus supplement dated June 30, 2026 for an offering of 35,555 units, each combining two shares of common stock and one warrant. The company is offering investors 71,110 shares of common stock along with 35,555 warrants to purchase up to a matching number of shares.¹ The offering price for each unit, consisting of two shares and one warrant, is $18.00.¹

Each warrant becomes exercisable on June 5, 2027, carries an $11.24 exercise price, and expires June 5, 2031.¹ The warrants carry a redemption price of $0.01 apiece¹ under conditions tied to the stock's trading price. On June 29, 2026, the last reported Nasdaq sale price for eXoZymes common stock was $8.42 per share.¹

MDB Capital, a wholly owned subsidiary of MDB Capital Holdings LLC, is acting as placement agent for the offering.¹ MDB Holdings is the company's largest shareholder, holding 4,136,426 shares, or 43.9% of common stock, immediately before the offering.¹

The company estimates net proceeds of approximately $565,206 after commissions and expenses.¹ Proceeds from this offering and a prior June 5, 2026 offering are intended to fund further development of the company's NCT business and related products, along with research, development, and general corporate purposes.¹

The filing also details the company's NCT (N-trans-caffeoyltyramine) program, aimed at metabolic disorders, and a subsidiary, NCTx LLC, formed to commercialize it. Separately, the company disclosed it was awarded a $2 million NIH grant to advance cannabinoid analogs for drug discovery, with funded work expected to begin July 1, 2026.¹ As of March 31, 2026, eXoZymes reported cash and cash equivalents of approximately $1,444,562 against an accumulated deficit of about $23,474,939.¹